Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Section for Preventive Cardiology

7 publications found

Bergum H, Sandven I, Klemsdal TO (2021)
Long-term effects (> 24 months) of multiple lifestyle intervention on major cardiovascular risk factors among high-risk subjects: a meta-analysis
BMC Cardiovasc Disord, 21 (1), 181
DOI 10.1186/s12872-021-01989-5, PubMed 33858345

Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP (2021)
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
JAMA Cardiol, 6 (2), 139-147
DOI 10.1001/jamacardio.2020.3151, PubMed 32785614

Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS, FOURIER Study Group (2021)
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
Circ J (in press)
DOI 10.1253/circj.CJ-20-1051, PubMed 33980763

Scholz JR, Abe TO, Gaya PV, Bellini B, de Moraes IRA, Santos JR, Tomaz PRX, de Lima Santos PC, Tonstad S (2021)
Cue restricted smoking increases quit rates with varenicline
Tob Prev Cessat, 7, 33
DOI 10.18332/tpc/133570, PubMed 34017927

Vallejo-Vaz AJ, Packard CJ, Ference BA, Santos RD, Kastelein JJP, Stein EA, Catapano AL, Pedersen TR, Watts GF, Ray KK (2021)
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
Atherosclerosis, 320, 1-9
DOI 10.1016/j.atherosclerosis.2021.01.003, PubMed 33497862

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S et al. (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Eur J Prev Cardiol (in press)
DOI 10.1093/eurjpc/zwab154, PubMed 34558602

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S et al. (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Eur Heart J, 42 (34), 3227-3337
DOI 10.1093/eurheartj/ehab484, PubMed 34458905

 
Page visits: 647406